Procyon Advisors LLC Has $1.72 Million Stake in Haleon plc (NYSE:HLN)

Procyon Advisors LLC raised its holdings in Haleon plc (NYSE:HLN) by 1.7% in the third quarter, Holdings Channel reports. The fund owned 162,911 shares of the company’s stock after acquiring an additional 2,755 shares during the period. Procyon Advisors LLC’s holdings in Haleon were worth $1,724,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in HLN. Syon Capital LLC grew its stake in Haleon by 31.4% in the fourth quarter. Syon Capital LLC now owns 67,711 shares of the company’s stock valued at $557,000 after acquiring an additional 16,175 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Haleon by 19.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after buying an additional 772,829 shares during the period. Wellington Management Group LLP boosted its position in shares of Haleon by 164.6% during the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after buying an additional 8,423,475 shares during the period. SageView Advisory Group LLC acquired a new position in shares of Haleon during the fourth quarter worth about $100,000. Finally, Sivia Capital Partners LLC acquired a new position in shares of Haleon during the fourth quarter worth about $93,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

HLN opened at $10.09 on Tuesday. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.80. The firm has a market capitalization of $46.07 billion, a PE ratio of 33.63, a PEG ratio of 2.93 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The business’s 50-day simple moving average is $10.18 and its 200 day simple moving average is $9.10.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The company had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter in the previous year, the company posted $0.08 EPS. As a group, sell-side analysts expect that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were paid a $0.0514 dividend. The ex-dividend date was Friday, August 16th. This represents a yield of 1.6%. Haleon’s dividend payout ratio is 33.33%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HLN. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Morgan Stanley upped their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Berenberg Bank started coverage on Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. Finally, UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Haleon has a consensus rating of “Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.